Market Research Report
Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||948123|
|Published||Pre-Order||Content info||200 Pages
Delivery time: 10 business days
|Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast - 2030|
|Published: Pre-Order||Content info: 200 Pages||
DelveInsight's 'Hereditary Angioedema (HAE) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Hereditary Angioedema (HAE), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hereditary Angioedema (HAE) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted HAE symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hereditary Angioedema (HAE) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Hereditary Angioedema (HAE) Overview
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx. It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon.
The clinical features of HAE are recurrent and unpredictable spontaneous edema attacks. Traumas, infections, stress, or medical procedures are potential triggers for HAE attacks, and occasionally, angioedema could be associated with prodromal signs, including erythema marginatum. The severity and timing of HAE attacks are unpredictable, mainly due to the lack of a complete understanding of the underlying mechanisms. Also, swelling without urticaria is the feature of most HAE attacks, regardless of the molecular basis
HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.
Despite advances in testing procedures and better disease recognition, the diagnosis of HAE still presents considerable challenges for physicians, particularly in the primary care setting. Diagnosis is made through a careful evaluation of clinical symptoms and family history and confirmed using laboratory testing.
Hereditary Angioedema (HAE) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Hereditary Angioedema (HAE) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Hereditary Angioedema (HAE) market report gives a thorough understanding of HAE symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides HAE symptoms of treatment algorithms and treatment guidelines for HAE symptoms in the US, Europe, and Japan.
The Hereditary Angioedema symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Hereditary Angioedema (HAE) epidemiology segmented as the Total diagnosed Prevalent of Hereditary Angioedema, Gender-specific cases of Hereditary Angioedema, Age-specific cases of Hereditary Angioedema, Type-specific cases of Hereditary Angioedema, Site-specific cases of Hereditary Angioedema, the report includes the Prevalent scenario of HAE symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Hereditary Angioedema (HAE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total Diagnosed Prevalent population of Hereditary Angioedema (HAE) in 7MM countries was estimated to be 14,435 cases in 2017.
The drug chapter segment of the Hereditary Angioedema (HAE) report encloses the detailed analysis of HAE marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hereditary Angioedema (HAE) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The market overall has been segmented into two treatment strategies that are commonly used for HAE are on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Long-term prophylaxis of attacks reduces disease burden, also Short-term (or periprocedural) prophylaxis treatment is taken before activities that are known to trigger attacks.
The goal of treatment for acute attacks is to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Treatments fall into three categories: C1-INH concentrates (plasma-derived [Berinert, CSL Behring] or Recombinant [Ruconest, Pharming Group]), kallikrein inhibitor (ecallantide [Kalbitor, Takeda]), and bradykinin receptor antagonist (icatibant [Firazyr, Takeda). Since treatment during an attack helps shorten attack duration, guidelines recommend the same. Medications for acute treatment are delivered either via intravenous infusion or subcutaneous injection, and home and/or self-administration are preferred due to the unpredictability of attacks.
Products detail in the report…
Hereditary Angioedema (HAE) Emerging Drugs
BCX7353 (BioCryst Pharmaceuticals)
BCX7353-also known as Berotralstat-is a novel, oral, once-daily, highly, selective inhibitor of plasma kallikrein currently in development for the prevention and treatment of angioedema attacks in patients diagnosed with HAE.
BioCryst Pharmaceuticals is actively preparing for commercial infrastructure for successful launches in the US & EU, and The FDA has accepted the NDA filing for BCX7353 and has also submitted a marketing authorization application (MAA) in Europe. For the Japan region, to ease the commercial activities company entered in agreement with Tori Pharmaceuticals. It has also been submitted JNDA of BCX7353as prophylactic treatment for HAE Type I and Type II. If approved, Berotralstat would be 1st approved prophylactic HAE therapy in Japan as well as in first targeted therapy in Europe. Besides, BioCryst Pharmaceuticals expects three regulatory approvals for Berotralstat in 2020 and early 2021 to prevent HAE attacks
Products detail in the report…
The Hereditary Angioedema (HAE) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Hereditary Angioedema (HAE) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Hereditary Angioedema (HAE) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Hereditary Angioedema (HAE) market in 7MM is expected to change in the study period 2017-2030.
At present, the therapeutic market size of HAE in the US is mainly accounted for by the management options consisting of various approved therapies.
Short-Term prophylaxis is aimed to prevent potentially fatal laryngeal edema. Medications for short-term prophylaxis are the same as those used for on-demand treatment. The goal of long-term prophylaxis for HAE patients is to prevent or reduce the frequency and severity of HAE attacks.
This section includes a glimpse of the Hereditary Angioedema (HAE) market in 7MM. The market size of HAE in the seven major markets was found to be USD 1,741.75 million in 2017.
This section provides the total Hereditary Angioedema (HAE) market size and market size by therapies in the United States.
The United States accounts for the highest market size of HAE in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Three classes of drugs - C1-INHs, 17 alpha-alkylated androgens, and antifibrinolytics - are currently being used for long-term prophylaxis of HAE type 1 and 2, and a monoclonal antibody, lanadelumab, was recently approved in the US and Europe for this indication.
The C1-INHs work by increasing the C1-INH levels in the body to prevent the accumulation of bradykinin and onset of angioedema. There are two C1-INH currently approved for long-term prophylaxis for HAE type 1 and 2 - Cinryze (Takeda) and Haegarda (CSL Behring).
The total Hereditary Angioedema (HAE) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Lanadelumab (Takhzyro, Takeda) is a newly-developed monoclonal antibody that was recently approved for long-term prophylaxis in HAE patients ages 12 and older. It inhibits plasma kallikrein, preventing the formation of bradykinin, and therefore, decreasing the risk of developing angioedema. It is administered subcutaneously every two or four weeks. The efficacy profile continues to position Takhzyro as a foundational HAE treatment in the US and good market opportunities in Germany, the UK, and other European regions.
"Both Haegarda and lanadelumab have the additional benefit of being subcutaneously administered, which may decrease the burden and complexity of administration and avoid complications due to repeated intravenous infusions"
The total Hereditary Angioedema (HAE) market size and market size by therapies in Japan are also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Hereditary Angioedema (HAE) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Hereditary Angioedema (HAE) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hereditary Angioedema (HAE) key players involved in developing targeted therapeutics.
Major players include of KVD900 (KalVista Pharmaceuticals) for acute treatment, and BCX7353 (BioCrystc Pharmaceuticals), IONIS-PKK-LRx (Ionis Pharmaceuticals), CSL312 (CSL Behring) for prophylaxis during the forecast period [2020-2030]. These therapies are novel and their approval will have tremendous effects on the future.
IONIS-PKK-LRx (Ionis Pharmaceuticals), is expected to get launched in the US market by 2024.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hereditary Angioedema (HAE) emerging therapies.
Reimbursement Scenario in Hereditary Angioedema (HAE)
Medications for HAE can be categorized into on-demand therapies, which are taken during an attack to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible. Short-term (or periprocedural) prophylaxis taken before activities is known to trigger attacks, whereas long-term prophylaxis reduces disease burden. Institute for Clinical and Economic Review (ICER) encouraged all stakeholders to suggest services (including treatments and mechanisms of care) that are currently used for people with HAE that could be reduced, eliminated, or made more efficient.
To keep up with current market trends, we take KOLs and SME's opinion working in Hereditary Angioedema (HAE) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hereditary Angioedema (HAE) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive & Market Intelligence analysis of the Hereditary Angioedema (HAE) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: